Total Aortic valve replacement market expected to be $7B USD or more by 2025THE RIGHT TIME FDA has approved TAVR in younger, lower risk patients creates need for ultra-durable valve THE RIGHT TECHNOLOGY DurAVR™ 3D single-piece aortic valve with ADAPT® tissue technology ▶ Superior resistance to calcification ▶ Scientific evidence of superior durability and hemodynamics THE RIGHT OPPORTUNITY TAVR in younger, lower risk patients creates need for ultra-durable valve ▶ADAPT® advantages support business development opportunities ▶ Path forward for partnering or independent TAVR development in select marketsOPPORTUNITY SUMMARYMore to come - parallel early-stage R&D: ▶ large potential markets for other structural heart indications, as well as non-structural heart indications, with potential to be best-in-class using ADAPT®
-----------------------------------------
This could start to get quite exciting in the coming months, providing there are no hiccups, which, going on the way this has progressed throughout and bringing all the right people on board to make it happen, I've got faith in seeing it take it's rightful position down the track. IMHO
